What are the latest trends and innovations you have observed in the treatment and management of multiple myeloma leading up to the European Hematology Association Hybrid Congress?
Let’s begin first with newly diagnosed multiple myeloma (NDMM). How has the paradigm of NDMM management shifted in recent history?